Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04953962 · ClinicalTrials.gov registry record · Phase 2
Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
A Phase 2 study, sponsored by CanBas Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT04953962 is a Phase 2 study that has completed, run by CanBas Co.. The registered enrollment target is 36 participants.
The verdict
NCT04953962, a Phase 2 study, has completed, sponsored by CanBas Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
Multicenter, randomized, open-label, parallel group phase 2 study to assess the efficacy and tolerance of four combinations of CBP501, cisplatin, and nivolumab administered once every 21 days to patients with stage IV exocrine pancreatic cancer and WBC \< 10,000/mm3 at screening.
Interventions
- DRUG Cisplatin
- DRUG Nivolumab
- DRUG CBP501 (16)
- DRUG CBP501 (25)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-12-18 |
| Est. Completion | 2023-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04953962
The ClinicalTrials.gov registry entry for NCT04953962 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CanBas Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT04953962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04953962 about?
NCT04953962 is a clinical study titled "Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer". Multicenter, randomized, open-label, parallel group phase 2 study to assess the efficacy and tolerance of four combinations of CBP501, cisplatin, and nivolumab administered once every 21 days to patients with stage IV exocrine pancreatic cancer and WBC \< 10,000/mm3 at screening.
What is the current status of trial NCT04953962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2021-12-18. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT04953962?
The interventions under investigation include: Cisplatin (DRUG), Nivolumab (DRUG), CBP501 (16) (DRUG), CBP501 (25) (DRUG).
Who is sponsoring clinical trial NCT04953962?
This trial is sponsored by CanBas Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.